Home  |  Contact

UniProtKB/Swiss-Prot P50995: Variant p.Gly38Arg

Annexin A11
Gene: ANXA11
Variant information

Variant position:  38
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Arginine (R) at position 38 (G38R, p.Gly38Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In ALS23; unknown pathological significance; changed cytoplasmic localization with decreased association with vesicle-like structures; increased interaction with S100A6.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  38
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  505
The length of the canonical sequence.

Location on the sequence:   PGGGPWGGAAYPPPPSMPPI  G LDNVATYAGQFNQDYLSGMA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PGGGPW-----GGAAYPPPPSMPPIGLDNVATYAGQFNQDYLSGMA

Mouse                         PGGGPW-----GGAGYPPPSMP-PIGLDNVANYAGQFNQDY

Bovine                        PGGGAW-----GGAGYPPPTMP-PIGLDNVANYAGQFNQDY

Rabbit                        PGGGAW-----GGAGYPPPSMP-PIGLDNVANYAGQFNQDY

Drosophila                    PFGAGWVPPMQQNSPYPPPSQPHPHSQPSSQMHPQQHQQ--

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 505 Annexin A11


Literature citations

Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.
Smith B.N.; Topp S.D.; Fallini C.; Shibata H.; Chen H.J.; Troakes C.; King A.; Ticozzi N.; Kenna K.P.; Soragia-Gkazi A.; Miller J.W.; Sato A.; Dias D.M.; Jeon M.; Vance C.; Wong C.H.; de Majo M.; Kattuah W.; Mitchell J.C.; Scotter E.L.; Parkin N.W.; Sapp P.C.; Nolan M.; Nestor P.J.; Simpson M.; Weale M.; Lek M.; Baas F.; Vianney de Jong J.M.; Ten Asbroek A.L.M.A.; Redondo A.G.; Esteban-Perez J.; Tiloca C.; Verde F.; Duga S.; Leigh N.; Pall H.; Morrison K.E.; Al-Chalabi A.; Shaw P.J.; Kirby J.; Turner M.R.; Talbot K.; Hardiman O.; Glass J.D.; De Belleroche J.; Maki M.; Moss S.E.; Miller C.; Gellera C.; Ratti A.; Al-Sarraj S.; Brown R.H. Jr.; Silani V.; Landers J.E.; Shaw C.E.;
Sci. Transl. Med. 9:0-0(2017)
Cited for: INVOLVEMENT IN ALS23; VARIANTS ALS23 ARG-38; GLY-40; ARG-175; GLU-189; GLN-235 AND CYS-346; CHARACTERIZATION OF VARIANTS ALS23 ARG-38; GLY-40; GLU-189 AND GLN-235; INTERACTION WITH S100A6; SUBCELLULAR LOCATION;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.